Get the Stockscreener App
19.80
7.48%
-1.60
After Hours:
19.00
-0.80
-4.04%
Travere Therapeutics Inc Stock (TVTX) Latest News
When the Price of (TVTX) Talks, People Listen - Stock Traders Daily
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat
Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan
Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat
Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Analyst Expectations For Travere Therapeutics's Future - Benzinga
Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Can Travere's March Conference Blitz Signal Major Development Updates? 4 Key Events to Watch - StockTitan
Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada
Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India
Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results - MarketBeat
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN
Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey
Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
Travere therapeutics chief medical officer sells $60k in stock - MSN
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... By GuruFocus - Investing.com Canada
Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks
Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Travere: Q4 Earnings Snapshot - San Antonio Express-News
Travere: Q4 Earnings Snapshot -February 20, 2025 at 04:27 pm EST - Marketscreener.com
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - Yahoo Finance
Travere Therapeutics earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
Entropy Technologies LP Makes New $214,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Travere Therapeutics (TVTX) Projected to Post Earnings on Thursday - MarketBeat
Leerink Partnrs Has Strong Forecast for TVTX FY2026 Earnings - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISI - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares - MarketBeat
Travere therapeutics director Roy Baynes sells $220,000 in stock - MSN
Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
William E. Rote Sells 5,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Eric M. Dube Sells 11,375 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Scotiabank Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Canaccord Genuity Group - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells $220,000.00 in Stock - MarketBeat
Travere therapeutics officer sells shares worth over $1.35 million - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):